Trinity Biotech plc announced on March 13, 2025, the appointment of Barclays Capital Inc. as its exclusive financial advisor to support an ongoing strategic realignment process. This move reflects the company’s increased focus on its continuous glucose monitoring (CGM) technology as part of its broader transformation plan. The board and management have determined that CGM technology and related data-driven insights will be the company's primary strategic focus moving forward.
CEO & President John Gillard stated that over the past year, the company has focused on proving the technological and market feasibility of building a large-scale, innovative global CGM business. Strong pre-pivotal clinical trial data and keen market interest for its more affordable, user-focused, and sustainable CGM solution provide confidence in this opportunity. The successful execution of Trinity Biotech’s comprehensive transformation plan is expected to drive near-term profitability improvements.
Barclays is now actively assessing how the company’s existing businesses can best align with this new strategic direction. This effort aims to create potential opportunities to optimize its portfolio and support CGM-related growth. The company intends to strategically allocate capital, optimize its balance sheet, and sharpen its focus on CGM growth.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.